SAB BIO announces positive topline Phase 1 clinical results with potentially disease-modifying T1D therapy SAB-142

SAB BIO, (“SAB BIO”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes…

Continue ReadingSAB BIO announces positive topline Phase 1 clinical results with potentially disease-modifying T1D therapy SAB-142

Advancing living materials with precise control over mechanical properties

Rice University researchers have revealed novel sequence-structure-property relationships for customizing engineered living materials (ELMs), enabling more precise control over their structure and how they respond to deformation forces like stretching…

Continue ReadingAdvancing living materials with precise control over mechanical properties

MaxCyte® acquires SeQure Dx to broaden cell engineering offerings with on-target and off-target editing assessments

MaxCyte, Inc., a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics announced today the acquisition of SeQure Dx, a market leader…

Continue ReadingMaxCyte® acquires SeQure Dx to broaden cell engineering offerings with on-target and off-target editing assessments